GZMB and classic Hodgkin lymphoma: Furthermore, the in vivo, ex vivo and in vitro successful application of GrB 201K-conferring fusion proteins were demonstrated in the design of hCFPs comprising wild-type GrB or GrBR201K fused to the antibody Ki4(scFv), which targets CD30 overexpressed on classical Hodgkin's lymphoma cells.